Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dL) must be obtained =< 7 days prior to protocol registration
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL)
Total bilirubin ? 1.5 mg/dL (upper limit of normal) except subject with documented Gilbert's syndrome (? 5 x ULN) or liver metastasis, who must have a baseline total bilirubin ? 3.0 mg/dL
Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
Bilirubin (total) within normal institutional limits (except subjects with Gilbert syndrome who must have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x the upper limits of normal (ULN), except for subjects with Gilbert Syndrome who can have bilirubin < 3
Total bilirubin should be =< 2 x upper limit of normal (ULN) (patients with Gilbert's syndrome must have a total bilirubin less than 3.0 mg/dL)
Bilirubin ?1.5x the upper limit of normal (ULN). For subjects with documented Gilbert's disease, bilirubin ?3.0 mg/dL. For subjects with documented liver metastases, bilirubin ? 2.5x ULN.
Obtained within 28 days prior to registration: Bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin within 1.5 x the upper limit of normal institutional limits; patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible, performed within 14 days prior to day 1 of protocol therapy
Total bilirubin < 1.5 x institutional normal limits (subjects with known Gilbert syndrome are eligible with total bilirubin < 3.0 mg/dL).
Total bilirubin =< 1.5 x normal institutional limits; for patients (Pts) with liver metastasis: total bilirubin must be within normal limits; (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
Total bilirubin =< 1.5 x ULN (upper limit of normal) except subject with documented Gilbert's syndrome (=< 5 x ULN) or liver metastasis, who must have a baseline total bilirubin =< 3.0 mg/dL
Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) except for patients with bilirubin elevation due to Gilbert's disease or of non-hepatic origin who will be allowed to participate, provided bilirubin is =< 3 x institutional ULN.
Total bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome who can have total bilirubin < 3.0 mg/dL)
Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined by: total bilirubin total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome or liver metastasis, who can have total bilirubin =< 3.0 x ULN)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), except patients with Gilbert's syndrome in whom total bilirubin must be < 3.0 mg/dL, within 2 weeks of registration (except where specified otherwise)
Total bilirubin =< 1.5 x upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
FULL STUDY INCLUSION CRITERIA: Total bilirubin =< 1.5 x the upper limit of normal (ULN); documented Gilbert syndrome is allowed if total bilirubin is mildly elevated (< 6 mg/dL)
Total bilirubin with 1.5 x the upper limit of normal (ULN) institutional limits; patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
To be performed within 10 business days prior to day 1: Total bilirubin within 1.5 x the upper limit of normal institutional limits; patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL), within 14 days prior to treatment
EXCEPTIONS:\r\n* Total bilirubin >= 5 mg/dL in patients with Gilbert's syndrome as defined by > 80% unconjugated\r\n* Total bilirubin >= 7.5 with direct fraction > 0.7 if patient is receiving a protease inhibitor at the time of initial evaluation\r\n* Hepatic dysfunction attributed to lymphoma, KSHV-MCD, or KICS
Total bilirubin =< 1.5 times the institutional upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin < 1.5 X institutional normal limits (subjects with known Gilbert syndrome are eligible with total bilirubin < 3.0 mg/dL)
Total bilirubin within 1.5 x the upper limit of normal institutional limits; patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total serum bilirubin =< 1.5 x upper limit of normal (ULN) (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 X normal institutional limits (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Within 14 days prior to study entry: Bilirubin =< 1.5 x upper limit of normal (ULN); except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL
Serum bilirubin within (or under) normal limits (OR total bilirubin =< 3.0 x institutional upper limit of normal [IULN] with direct bilirubin within normal range in patients with well documented Gilbert syndrome)
Total bilirubin within normal institutional limits (patients with Gilbert's syndrome must have a total bilirubin < 3.0 mg/dL)
Total bilirubin ? 1.5 x upper limit of normal (ULN) (except patients with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome with a total bilirubin < 3.0 mg/dL)
Total bilirubin\r\n* If no known liver metastases:\r\n** Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except subjects with Gilbert syndrome, who may have total bilirubin < 3.0 mg/dl)\r\n* If known metastasis:\r\n** Total bilirubin =< 5 ULN
Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with Gilbert syndrome, who can have total bilirubin < 3 mg/dl)
Total bilirubin within normal institutional limits; EXCEPTION: subjects with known Gilbert's disease: total bilirubin =< 3 x institutional upper limit of normal (ULN)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin ? 1.5 upper limit of normal (ULN), except for participants with Gilbert's syndrome as defined by > 80% unconjugated bilirubin and total bilirubin ? 6 mg/dL
Total bilirubin within normal institutional limits, patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) except for patients with bilirubin elevation due to Gilbert's disease who will be allowed to participate
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (except patients with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL)
Total bilirubin =< 1.5 X institutional upper limit of normal\r\n* Note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator
Total bilirubin levels ? 1.5 x upper limit of normal [ULN] (except for patients with Gilbert's Syndrome, who must have a total bilirubin of less than 3.0 mg/dL)
Total bilirubin =< upper limit of normal (ULN) except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL
Serum bilirubin =< 1.5 times the upper institutional limits of normal (ULN); patients with a history of Gilbert's syndrome may be enrolled if the total bilirubin is < 3 mg/dL with a predominance of indirect bilirubin
Total bilirubin =< 2.5 x upper limit of normal (ULN) unless due to Gilbert's disease; for those with a total bilirubin > 2.5 x ULN, a direct bilirubin should be performed and must be < 1.5 mg/dL for Gilbert's to be diagnosed; if value is higher due to hepatic involvement by CLL, patient is eligible
Total bilirubin within normal institutional limits; for patients with Gilbert's syndrome, total bilirubin =< 3.0 mg/dL
Total bilirubin =< 1.2 mg/dL; for patients with Gilbert syndrome, the direct bilirubin should be within the institutional normal range
Total bilirubin =< 1.5 x institutional limits unless documented Gilbert's syndrome (then < 2.5 x institutional upper limit)
Bilirubin < 1.5x ULN (except for patients with Gilbert's disease, for whom the upper acceptable limit of serum bilirubin is 3mg/dL)
Total bilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL
Total bilirubin =< 1.5 x institutional upper limit of normal; Note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator
Total bilirubin ? 1.5 x the upper limit of normal (ULN). Mildly elevated total bilirubin (< 6 mg/dL) is allowed if Gilbert's syndrome is documented.
Total bilirubin =< 1.5 x institutional upper limit of normal; note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator
Bilirubin =< 1.5 x the upper limit of normal (ULN); for subjects with known Gilbert's disease, bilirubin =< 3.0 mg/dL
Total bilirubin within 1.5 x of the upper limit of normal (ULN) institutional limits, patients with elevation of unconjugated bilirubin alone, as in Gilbert's disease, are eligible
Serum bilirubin ? 1.5 times the upper limits of normal. Subjects with a history of Gilbert's syndrome may be enrolled if the total bilirubin is < 3 mg/dL with an indirect bilirubin of > 1.5 mg/dL
